Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anna Willms"'
Autor:
Anna Willms, Hella Schupp, Michelle Poelker, Alshaimaa Adawy, Jan Frederik Debus, Torsten Hartwig, Tim Krichel, Jürgen Fritsch, Steven Singh, Henning Walczak, Silvia von Karstedt, Heiner Schäfer, Anna Trauzold
Publikováno v:
Cell Death and Disease, Vol 12, Iss 8, Pp 1-12 (2021)
Abstract TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2) can induce apoptosis in cancer cells upon crosslinking by TRAIL. However, TRAIL-R2 is highly expressed by many cancers suggesting pro-tumor functions. Indeed, TRAIL/TRAIL-R2
Externí odkaz:
https://doaj.org/article/01faaca6a4584d9ebb8d543b9bdea437
Autor:
Anna Willms, Hella Schittek, Sascha Rahn, Justyna Sosna, Ufuk Mert, Dieter Adam, Anna Trauzold
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0214847 (2019)
Due to their ability to preferentially induce cell death in tumor cells, while sparing healthy cells, TNF-related apoptosis-inducing ligand (TRAIL) and agonistic anti-TRAIL-R1 or anti-TRAIL-R2-specific antibodies are under clinical investigations for
Externí odkaz:
https://doaj.org/article/b399ac7566e0450e9157f35b7a9e1750
Autor:
Christian Röder, Sandra Krüger, Christine Halske, Anna Trauzold, Jan-Paul Gundlach, Anna Willms, Franka Maria Schlegel, Holger Kalthoff, Charlotte Hauser, Thomas E. Becker, Christoph Röcken
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose HMGA2 has frequently been found in benign as well as malignant tumors and a significant association between HMGA2 overexpression and poor survival in different malignancies was described. In pancreatic ductal adenocarcinoma (PDAC), nuclear HM
Autor:
Ufuk Mert, Verena Haselmann, Anna Trauzold, Anna Willms, Johannes Lemke, Juergen Fritsch, Cynthia Colmorgen, Pierre Teichmann, Silvia von Karstedt, Elisabeth Scharff, Alshaimaa Adawy
Publikováno v:
Cancers
Volume 11
Issue 8
Cancers, Vol 11, Iss 8, p 1167 (2019)
Volume 11
Issue 8
Cancers, Vol 11, Iss 8, p 1167 (2019)
Binding of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to the plasma membrane TRAIL-R1/-R2 selectively kills tumor cells. This discovery led to evaluation of TRAIL-R1/-R2 as targets for anti-cancer therapy, yet the corresponding c
Autor:
Dieter Adam, Ufuk Mert, Sascha Rahn, Anna Trauzold, Anna Willms, Hella Schittek, Justyna Sosna
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0214847 (2019)
PLoS ONE
PLoS ONE
Due to their ability to preferentially induce cell death in tumor cells, while sparing healthy cells, TNF-related apoptosis-inducing ligand (TRAIL) and agonistic anti-TRAIL-R1 or anti-TRAIL-R2-specific antibodies are under clinical investigations for
Autor:
Charlotte Hauser, Carola Heneweer, Thomas Becker, Anna Trauzold, Harald Fricke, Anna Willms, Johannes Lemke, Michael Kluge, Jan-Hendrik Egberts, Holger Kalthoff, Christoph Röcken, Karen Legler, Susann Boretius, Christian Gieffers, Oliver Hill, Claus-Christian Glüer
Publikováno v:
Cell Death and Disease, Vol 9, Iss 5, Pp 1-15 (2018)
Cell Death & Disease
Cell Death & Disease
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has raised attention as a novel anticancer therapeutic as it induces apoptosis preferentially in tumor cells. However, first-generation TRAIL-receptor agonists (TRAs), comprising recombi
Publikováno v:
Antioxidantsredox signaling. 25(1)
Mitochondria play a central role in the maturation of proteins with iron-sulfur (Fe/S) clusters. During their biogenesis, the apoforms of Fe/S proteins expose unprotected Fe/S cluster-coordinating cysteine side chains, rendering them vulnerable to ox
Autor:
Juergen E. Gschwend, Anna Willms, Kathleen Herkommer, Peter Herschbach, Andreas Dinkel, Birgit Marten-Mittag
Publikováno v:
Journal of Urology. 193